Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Assets: 2014-2025

Historic Assets for Zevra Therapeutics (ZVRA) over the last 10 years, with Sep 2025 value amounting to $270.1 million.

  • Zevra Therapeutics' Assets rose 41.02% to $270.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $270.1 million, marking a year-over-year increase of 41.02%. This contributed to the annual value of $178.1 million for FY2024, which is 3.37% up from last year.
  • According to the latest figures from Q3 2025, Zevra Therapeutics' Assets is $270.1 million, which was up 5.40% from $256.3 million recorded in Q2 2025.
  • Zevra Therapeutics' Assets' 5-year high stood at $270.1 million during Q3 2025, with a 5-year trough of $90.4 million in Q1 2021.
  • Over the past 3 years, Zevra Therapeutics' median Assets value was $172.3 million (recorded in 2023), while the average stood at $171.6 million.
  • Its Assets has fluctuated over the past 5 years, first spiked by 1,124.44% in 2021, then decreased by 15.20% in 2023.
  • Over the past 5 years, Zevra Therapeutics' Assets (Quarterly) stood at $132.9 million in 2021, then decreased by 13.24% to $115.3 million in 2022, then skyrocketed by 49.41% to $172.3 million in 2023, then increased by 3.37% to $178.1 million in 2024, then spiked by 41.02% to $270.1 million in 2025.
  • Its Assets stands at $270.1 million for Q3 2025, versus $256.3 million for Q2 2025 and $172.7 million for Q1 2025.